Autoimmune Disease and Heart Disease in Men: The Inflammatory Risk Nobody Mentions

Most men who have psoriasis think about it as a skin condition. They manage flares, use topical treatments, and follow up with dermatology. Most men with ankylosing spondylitis think about their spine — the morning stiffness, the restricted range of motion, the management of a progressive musculoskeletal disease. What few men with these conditions are told, clearly and directly, is that the same inflammatory pathways driving their visible disease are also driving atherosclerosis in their coronary arteries — silently, continuously, for years before any cardiac symptom appears.

Systemic autoimmune and inflammatory diseases are among the most under-recognized cardiovascular risk factors in men. The conditions affecting men at the highest rates — psoriasis, ankylosing spondylitis, gout, inflammatory bowel disease, and rheumatoid arthritis when it occurs in men — all share a common cardiovascular mechanism: chronic systemic inflammation that accelerates the atherogenic process at a rate that exceeds what traditional risk factors would predict.

The Shared Mechanism: Inflammation and the Coronary Artery

Atherosclerosis is an inflammatory disease. The formation and progression of coronary artery plaque is not simply a passive accumulation of cholesterol; it is an active inflammatory process in which immune cells, cytokines, and endothelial dysfunction all play central roles. LDL particles that enter the arterial wall are oxidized, triggering a local inflammatory response. Macrophages engulf oxidized LDL and become foam cells — the cellular core of atherosclerotic plaque. Inflammatory cytokines drive smooth muscle cell migration and proliferation, contributing to plaque growth. Plaque vulnerability — the likelihood of rupture and thrombosis — is determined in large part by the degree of ongoing inflammation at the plaque cap.

When a man has a systemic autoimmune or inflammatory disease, the circulating inflammatory mediators that his immune system produces for the primary disease — TNF-alpha, IL-1, IL-6, IL-17, IL-23 — are not confined to the skin, joints, or spine. They circulate throughout the body. They act on coronary artery endothelial cells, driving upregulation of adhesion molecules (VCAM-1, ICAM-1) that recruit more immune cells. They reduce nitric oxide bioavailability, impairing endothelial vasodilation. They accelerate oxidation of LDL within the arterial wall. The result is a coronary artery that ages faster than a comparably-risky man without systemic inflammation.

The cardiovascular risk from inflammatory disease is additive to and largely independent of traditional risk factors. A man with psoriasis and a 10-year ASCVD risk of 10 percent on the Pooled Cohort Equation has a true cardiovascular risk that is higher than that 10 percent — sometimes substantially higher — because the calculator does not account for the atherogenic effect of his chronic skin inflammation.

Psoriasis: The Cardiovascular Risk Men Are Not Told About

Psoriasis affects approximately 3 percent of men in the United States, and its prevalence is roughly equal between sexes. Among men with psoriasis, the cardiovascular implications are documented and dose-dependent.

The largest meta-analyses of psoriasis and cardiovascular risk show that men with severe psoriasis — defined by body surface area involvement or by psoriasis area and severity index (PASI) scores — have a 30 to 58 percent higher rate of major adverse cardiovascular events (MACE) compared to men without psoriasis, after adjusting for smoking, hypertension, diabetes, and lipid levels. The risk for men with mild psoriasis is smaller but still elevated at approximately 10 to 15 percent above the expected rate.

The mechanistic driver is a TNF-alpha and IL-17/IL-23 axis inflammatory cascade. These cytokines originate in psoriatic plaques and circulate systemically. They act on coronary endothelium, promote arterial inflammation, accelerate plaque formation, and are associated with higher rates of plaque vulnerability markers on coronary imaging.

Psoriatic arthritis — which develops in 20 to 30 percent of men with psoriasis — carries additional cardiovascular risk beyond psoriasis alone. The joint inflammation adds another atherogenic inflammatory stimulus. Men with psoriatic arthritis have cardiovascular risk profiles similar to those seen in rheumatoid arthritis.

The cardiovascular implication is practical: a man with significant psoriasis who has not had his cardiovascular risk explicitly recalibrated with his psoriasis factored in has received an incomplete risk assessment. Standard cardiovascular risk calculators do not include inflammatory disease. Dermatologists rarely frame psoriasis in cardiovascular terms. Cardiologists rarely ask about skin conditions. The gap is systematic.

Ankylosing Spondylitis: Cardiac Involvement Beyond Atherosclerosis

Ankylosing spondylitis affects men at approximately a 3-to-1 ratio compared to women. It is a seronegative spondyloarthropathy driven by HLA-B27 positivity and IL-23/IL-17 pathway inflammation, causing progressive vertebral and sacroiliac joint fusion along with enthesitis (inflammation at tendon and ligament insertion points).

The cardiovascular involvement in AS operates through two distinct mechanisms.

The first is accelerated systemic atherosclerosis through chronic inflammation — the same TNF/IL-17 pathway described for psoriasis, with similar effects on endothelial function and atherogenesis. Men with AS have approximately 25 to 50 percent higher cardiovascular mortality than men without AS in multiple Scandinavian registry studies with long follow-up.

The second is direct cardiac structural involvement that is specific to AS and has no equivalent in most inflammatory conditions affecting women predominantly. Inflammation in AS specifically involves the aortic root — the tissue around the origin of the aorta from the left ventricle. Aortitis in AS can produce:

Aortic regurgitation — incomplete closure of the aortic valve due to aortic root dilation from inflammation. Aortic regurgitation is present in 1 to 10 percent of men with AS, proportional to disease duration. In long-standing AS, the prevalence is higher. This is not a plaque-mediated cardiac complication; it is a direct structural consequence of the inflammatory disease.

Cardiac conduction abnormalities — inflammation extending to the AV node and bundle branches can produce varying degrees of heart block and bundle branch block. First-degree AV block is found in up to 33 percent of men with AS; higher-degree block requiring pacemaker implantation occurs in a smaller but clinically significant proportion. Men with AS and palpitations, near-syncope, or fatigue should have ECG evaluation even in the absence of exertional symptoms.

Rheumatoid Arthritis in Men: When Men Get a Women’s Disease

Rheumatoid arthritis affects women approximately three times as commonly as men. When it occurs in men, it tends to present with a different phenotype: often more severe, more frequently seropositive (rheumatoid factor and anti-CCP positive), with higher rates of systemic extra-articular involvement.

Men with RA have approximately twice the cardiovascular mortality of men without RA in prospective data. The absolute cardiovascular risk is higher in men with RA than in women with RA because men start from a higher baseline cardiovascular risk. The 1.5x cardiovascular risk multiplier recommended by EULAR for RA patients applies to both sexes, but the absolute risk it is multiplied against is larger in men.

The atherogenic mechanism in RA includes chronic TNF-alpha and IL-6 elevation, which drive endothelial dysfunction and accelerate plaque formation. RA is also associated with lipoprotein abnormalities — particularly a pro-atherogenic lipid pattern (lower HDL, higher small dense LDL fraction, elevated Lp(a) in some series) — that amplify the inflammatory cardiovascular risk. Men with RA who also have poorly controlled lipids have a compounding risk profile.

Gout: The Underappreciated Cardiovascular Marker

Gout is an inflammatory disease driven by monosodium urate crystal deposition. It is predominantly a disease of men — affecting men at approximately four times the rate of women in middle age. Gout is typically framed as a joint disease with pain management as the primary concern.

From a cardiovascular standpoint, gout is simultaneously a consequence and a driver of cardiometabolic risk. Hyperuricemia — the elevated uric acid level that predisposes to gout — is associated with hypertension, insulin resistance, renal impairment, and endothelial dysfunction. Whether uric acid is a direct causal cardiovascular risk factor or a marker of underlying metabolic disease is debated; the association is robust and the mechanism plausible (uric acid promotes RAAS activation and oxidative stress in endothelial cells).

Men with recurrent gout have significantly higher rates of cardiovascular events than men without gout even after adjusting for the metabolic comorbidities that cluster with hyperuricemia. Men presenting with a first gout attack at age 40 to 55 should trigger a comprehensive cardiometabolic risk evaluation — not because gout caused their cardiovascular risk, but because gout at that age in a man is a reliable signal that hyperuricemia, metabolic dysfunction, hypertension, and elevated cardiovascular risk are co-present.

NSAIDs: When the Treatment Adds to the Risk

Non-steroidal anti-inflammatory drugs are among the most commonly used medications for inflammatory pain in men with AS, psoriatic arthritis, gout, and RA. They are effective for symptom management. They also carry cardiovascular risk.

Selective COX-2 inhibitors — celecoxib, etoricoxib — increase cardiovascular events by inhibiting prostacyclin production without inhibiting thromboxane A2, tilting the platelet-vascular balance toward prothrombotic and vasoconstrictive states. The VIGOR trial (rofecoxib) and the APPROVE trial established this risk definitively enough that rofecoxib was withdrawn from market. The remaining COX-2 inhibitors carry warnings.

Non-selective NSAIDs (ibuprofen, naproxen, diclofenac) carry lower cardiovascular risk than selective COX-2 inhibitors, but not zero risk. Naproxen has the most favorable cardiovascular profile among traditional NSAIDs based on multiple meta-analyses. Diclofenac has a cardiovascular risk profile closer to selective COX-2 inhibitors despite being non-selective.

For men with inflammatory disease who are already at elevated cardiovascular risk from their disease, the routine use of high-dose NSAIDs for joint pain adds a second cardiovascular burden. Optimizing disease control with disease-modifying agents — which can reduce the need for NSAIDs — is a cardiovascular management strategy, not just a rheumatological one.

Anti-TNF Biologics: Possible Cardiovascular Benefit

A finding that has emerged from large observational registries of patients on biologic therapies for psoriasis, AS, and RA is that anti-TNF agents — adalimumab, etanercept, infliximab, certolizumab — appear to reduce cardiovascular events beyond what would be expected from disease control alone.

In the PsA and psoriasis registries, men on anti-TNF therapy have lower MACE rates than men on non-biologic treatments with similar disease severity. In RA registries, anti-TNF therapy and methotrexate have each been associated with reduced cardiovascular mortality compared to expectation. The mechanism is the systemic removal of the inflammatory mediators driving both joint disease and atherogenesis.

This data point has a clinical implication: for men with inflammatory disease where biologic therapy is appropriate for disease control, the decision for or against biologic therapy should include the cardiovascular risk reduction potential as a factor — not just the rheumatological or dermatological justification.

Coronary Artery Calcium Scoring in Men with Inflammatory Disease

Standard cardiovascular risk calculators — the Pooled Cohort Equations, the Framingham Risk Score — were developed in population samples that did not include people with systemic inflammatory diseases at the rates they occur in clinical practice. They do not have an input for psoriasis severity, AS diagnosis, or RA duration. Applying a post-hoc multiplier (1.5x for RA per EULAR) improves the estimate but still relies on a baseline calculation that was never calibrated for inflammatory disease populations.

For men with psoriasis, AS, RA, or inflammatory bowel disease, coronary artery calcium (CAC) scoring provides a direct measurement of atherosclerotic burden that bypasses the limitations of risk-score estimation. A CAC score of zero in a man with severe psoriasis who is otherwise low-risk provides strong reassurance and justifies a lower-intensity prevention approach. A CAC score of 200 in the same man establishes that his inflammatory disease has already accelerated atherogenesis to a degree that meets the threshold for statin initiation even if his calculated 10-year risk would not, in isolation, have crossed that threshold.

The 2019 ACC/AHA cholesterol guidelines specifically list “inflammatory diseases such as psoriasis, rheumatoid arthritis, or lupus” as risk-enhancing factors that support the use of CAC scoring when the treatment decision remains uncertain after standard risk estimation. For men with moderate to severe inflammatory disease who are in the intermediate-risk range (7.5 to 20 percent 10-year ASCVD risk), CAC scoring provides the direct plaque-burden data that replaces estimation with measurement.

The practical recommendation: a man with significant psoriasis (PASI above 10 or requiring systemic therapy), established AS, or RA who is 45 or older and has not had a CAC score should discuss whether one is appropriate. The low radiation exposure of a CAC scan, its ability to be performed without contrast, and the directness of the information it provides make it a well-suited risk-stratification tool for men whose inflammatory disease makes standard estimation inadequate.

What to Do This Week

If you have psoriasis, ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis, or inflammatory bowel disease and you have not had a formal cardiovascular risk assessment that explicitly accounts for your inflammatory condition, request one. Standard Pooled Cohort Equations do not include inflammatory disease. The assessment should either apply a risk multiplier (EULAR recommends 1.5x for RA; similar approaches apply for psoriasis and AS) or directly measure atherosclerotic burden with a coronary artery calcium score.

If you are on NSAIDs regularly for joint pain, ask your treating physician whether your cardiovascular risk profile warrants a switch to naproxen (lowest-risk NSAID) or escalation to a disease-modifying agent that would reduce NSAID dependency.

Ask your rheumatologist or dermatologist to communicate directly with your cardiologist or primary care physician about the cardiovascular implications of your inflammatory disease. These specialties frequently operate in parallel without a shared cardiovascular risk conversation. The man with severe psoriasis who is seen twice yearly by dermatology and annually by his internist may have neither specialist tracking his cardiovascular risk as a function of his skin disease.